Biotech

All Articles

A closer take a look at Fierce Biotech's Fierce 15

.Within this full week's episode of "The Leading Line," our experts are actually diving in to Fierce...

Lilly encounters period 2 breakdown of tau-targeting med

.The confetti is still flying from Eli Lilly's gathering commemorating the approval of Alzheimer's i...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of considerable management hirings, shootin...

Lykos will definitely talk to FDA to reassess its own selection adhering to being rejected of MDMA treatment for post-traumatic stress disorder

.Following a poor presenting for Lykos Therapeutics' MDMA candidate for trauma at a current FDA cons...

AN 2 fifty percents head count, quits phase 3 trial after information dissatisfy

.AN2 Therapeutics is reviewing its service in action to uninspired midphase information, swearing to...

Merck spends $700M for bispecific, snooping autoimmune opening and also possibility to test Amgen in cancer cells

.Merck &amp Co. is paying $700 million in advance to test Amgen in a blood stream cancer cells marke...

Gilead pays out J&ampJ $320M to go out licensing deal for seladelpar

.With Gilead Sciences on the verge of an FDA choice for its liver condition drug seladelpar, the pro...

' All palms on deck' at Lilly as peers target obesity market

.CEO David Ricks may observe the firms setting up tents at basecamp responsible for Eli Lilly in an ...

Entero laying off team, moving out of office and stopping briefly R&ampD

.Bed mattress Liquidators has turned Entero Therapies white colored as a sheet. The collector purcha...

Exelixis goes down ADC after choosing it's no suit for Tivdak

.Exelixis is surrendering on its tissue aspect (TF)- targeting antibody-drug conjugate after wrappin...